Date: 2014-04-02
Type of information: Licensing agreement
Compound: Sitavig®/Sitavir® (Acyclovir Lauriad®)
Company: BioAlliance Pharma (France) Daewoong Pharmaceutical (South Korea)
Therapeutic area: Infectious diseases
Type agreement: licensing
commercialisation
Action mechanism:
Disease: recurrent labial herpes
Details: * On April 2, 2014, BioAlliance Pharma, an innovative Company specialized in the development of drugs in orphan oncology diseases, has announced an exclusive supply and license agreement for Sitavig® (Acyclovir Lauriad®) with Daewoong Pharmaceutical Co., Ltd. for commercialization rights in South Korea. Moreover, Daewoong will be in charge of registering Sitavig® in South Korea. Under this agreement, BioAlliance Pharma is eligible to receive significant upfront and milestones payments. The agreement also includes a double-digit royalty rate which should represent high downstream revenues.
Financial terms:
Latest news:
